drugset / Trial / NCT06716190

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

NCT06716190

Phase 1 Terminated 30 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.

Timeline

Start
2024-12-18
Primary completion
2025-05-19
Completion
2025-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3731579 Unknown
Background Midazolam Small molecule

Indications

No indication recorded.